Accordingly, this strategy may offer a new, α-cell centric approach to the treatment of certain patients with type 1 diabetes that complements the role of SIRT1 in preventing organ-specific autoimmunity8. This evidence concerns the gene SIRT1 and type 1 diabetes mellitus.